SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates the potential launch of a spot XRP ETF, with discussions focusing on the possible impact on price and market dynamics. Bullish sentiment is fueled by expectations of increased institutional investment and potential supply shock, while some caution against overhyping near-term gains. Chatter also includes the government shutdown ending and how that may affect crypto.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is experiencing volatility, with community discussions focusing on a potential market correction despite anticipation surrounding the government reopening; some traders believe the end of the government shutdown will provide much-needed liquidity, while others express concern over potential manipulation and the lack of a significant price surge following the news. Mixed sentiment prevails, with some anticipating a drop towards lower support levels and others suggesting an oversold condition ripe for a rebound.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as community members discuss recent overnight action and positive data readouts, with many highlighting upcoming catalysts and institutional investment. The conversation centers on the potential for a squeeze, with some suggesting a return to previous highs given upcoming FDA meetings. Community members see it as undervalued.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending amid discussions around upcoming earnings and the potential impact of the lock-up period expiration, with some traders anticipating a significant drop while others remain bullish. Community members are debating the company's valuation, growth prospects, and competitive positioning in the stablecoin market, with some highlighting insider selling and potential dilution concerns. Despite recent price declines, some investors express optimism about CRCL's long-term potential as a key player in the evolving digital finance landscape.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney's stock is trending as investors anticipate upcoming earnings results and assess the impact of a recent distribution dispute with YouTube TV, which has caused some channel blackouts. Community discussions revolve around the potential for a positive earnings surprise and the company's streaming strategy, with some expressing concerns about content and pricing. Bullish sentiment appears to be building as analysts weigh in on the stock's potential, with a focus on the company's experiences segment and intellectual property monetization.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await the EMA's decision on Blarcamesine, with discussions focusing on potential approval pathways and the drug's benefits in Alzheimer's treatment. Community chatter revolves around short squeeze potential, the significance of the oral explanation, and speculation on the decision's timing. Despite recent price volatility, longs remain optimistic about the drug's prospects and its potential impact on the Alzheimer's landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amid renewed buyout speculation after Pfizer's Metsera deal, with investors eyeing VKTX as a potential target given its promising obesity and MASH pipeline. Community discussions revolve around the stock's valuation, potential acquisition price, and the possibility of a partnership with a major healthcare player. Bullish sentiment is fueled by analysts' positive outlook and the belief that VKTX is undervalued compared to its peers in the competitive weight loss market.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid concerns about debt related to AI buildouts, despite secure contracts with hyperscalers. Community discussions revolve around whether this dip presents a buying opportunity, with some drawing comparisons to Coreweave's situation. Bulls express confidence in long-term fundamentals and potential government contracts.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to Shah Capital's renewed push for a company sale, citing frustration with management's performance and a perceived lack of competence, even suggesting intentional underperformance; the community is rallying behind the activist investor, expressing shared concerns about leadership and strategic direction and debating the likelihood and impact of a potential proxy fight or acquisition amid skepticism about current management's ability to unlock value, while highlighting the potential of the Matrix-M adjuvant technology.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

$FNMA is trending as investors react to ongoing speculation around a potential IPO and government actions related to Fannie Mae and Freddie Mac. Community members are closely watching for updates following meetings between key figures and expressing varied opinions on the potential outcomes for common shareholders, with government actions remaining a central focus.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Clear Street cut its price target to $7 from $93, saying KRRO-110 failed to reach protective protein levels in its Phase 1/2 study for Alpha-1 Antitrypsin Deficiency.</li><li>Korro said differences between healthy volunteers and patients guided its pivot to a GalNAc delivery approach, with a new AATD candidate expected in early 2026.</li><li>Retail traders on StockTwits pointed to the company’s cash position and second pipeline program.</li></ul>Korro Bio shares crashed over 75% after-hours on Wednesday after analysts downgraded the stock and the company said it would cut about 34% of its workforce following disappointing results from its lead drug for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic condition in which the liver does not make enough of a protein needed to protect the lungs.<h2 class="st-heading-2">Analyst Downgrades&nbsp;</h2>Clear Street downgraded Korro Bio to ‘Hold’ from ‘Buy’ and cut its price target to $7 from $93. The analyst said KRRO-110 failed to&nbsp;achieve protective levels of the corrected protein in its Phase 1/2 trial for Alpha-1 Antitrypsin Deficiency, leading to the discontinuation of development. The analyst also said that with the step back in timeline and the move away from its lipid nanoparticles (LNP) delivery approach, Korro’s positioning in the disorder is “compromised.”Cantor Fitzgerald also downgraded the stock, moving its rating to ‘Neutral’ from ‘Overweight’.<h2 class="st-heading-2">Lead Drug Falls Short In Early Trial</h2>Korro said KRRO-110 did produce functional protein in patients with Alpha-1 Antitrypsin Deficiency, but did not reach the levels it predicted from earlier preclinical work. The company said differences between healthy volunteers and AATD patients contributed to its pivot toward a new delivery approach called GalNAc. A new AATD development candidate using this approach is expected in the first half of 2026.<h2 class="st-heading-2">Pipeline Pivot</h2>Korro also nominated KRRO-121, a GalNAc-conjugated RNA-editing therapy designed for patients with hyperammonemia. The company plans to move the program into clinical testing in the second half of 2026.<h2 class="st-heading-2">Workforce Reduction&nbsp;</h2>Korro said it will reduce its workforce by nearly 34%, with the cuts affecting all levels of the organization. The company said the restructuring is expected to extend its cash runway into the second half of 2027, giving it sufficient capital to deliver clinical data from KRRO-121, advance at least one additional program, and conduct partnership discussions to broaden pipeline development.Korro also said it expects to incur about $2.4 million in one-time restructuring charges, including employee severance, benefits, and related termination costs, most of which it expects to recognize during the fourth quarter of 2025.<h2 class="st-heading-2">Executive Exit</h2>Korro said Chief Medical Officer Kemi Olugemo resigned, effective Wednesday. The company ended the third quarter with $102.5 million in cash, cash equivalents, and marketable securities. Collaboration revenue for the period was $1.1 million, and net loss totaled $18.1 million.<h2 class="st-heading-2">Stocktwits Users Flag Cash Position&nbsp;</h2>On Stocktwits, retail sentiment for Korro was ‘extremely bullish’ amid ‘extremely high’ message volume, placing it among the top five trending equities on the platform.&nbsp;<figure class="image"><img style="aspect-ratio:970/145;" src="https://news.stocktwits-cdn.com/krro_ss_jpg_f7790cba96.webp" alt="krro ss.jpg" width="970" height="145"><figcaption>KRRO sentiment and message volume as of November 12 | Source: Stocktwits</figcaption></figure>One user suggested the stock could recover toward $10 in the morning, noting the company has ample cash and another program in development that could resonate with investors.<stembedurl>https://stocktwits.com/murphylaw/message/635974154</stembedurl>Another user said the pullback was a buying opportunity, arguing that the company has significant cash on hand and a second product in the pipeline.<stembedurl>https://stocktwits.com/murphylaw/message/635976345</stembedurl><a href="https://stocktwits.com/symbol/KRRO">Korro’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Korro’s stock (KRRO) has declined 17% so far in 2025. (Photo credit: Getty Images)

Korro Bio Stock Crashes Over 75% After-Hours On Drug Failure, Downgrades And Layoffs — Yet Retail Flags ‘Buy-The-Fear’ Setup

Clear Street cut its price target to $7 from $93, saying KRRO-110 failed to reach protective protein levels in its Phase 1/2 study for Alpha-1 Antitrypsin Deficiency.

Equity

Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates

Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of +26.44% and -27.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

180 Life Sciences (ATNF) 180 Life Sciences surged more than 500% on Wednesday becoming the top gainer across U.S. exchanges, boosting retail sentiment.The <a href="https://stocktwits.com/news-articles/markets/equity/atnf-stock-surges-on-online-gaming-pivot/cJcz40JRIG">sharp rally</a> followed the company’s announcement of its strategic pivot into online gaming, or iGaming, a move that seems to have sent retail investors into a frenzy.Retail sentiment on Stocktwits has skyrocketed to ‘extremely bullish’ (97/100) from ‘neutral’ a day ago.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_223155_cd82ae123f.png" alt="Screenshot 2024-10-16 223155.png">NuScale Power Corp. (SMR)NuScale Power shares surged 33% on Wednesday, buoyed by <a href="https://stocktwits.com/news-articles/markets/equity/amazon-signs-agreements-to-support-nuclear-energy-development/cJcza0dRIc">Amazon's decision</a> to invest in nuclear energy to power its data centers and other facilities at its Washington state headquarters.NuScale specializes in small modular reactors (SMRs), the same cutting-edge technology Amazon is considering to meet its growing energy demands. The stock soared to an all-time high of $18.01, marking a remarkable 473% year-to-date increase.Retail sentiment on Stocktwits has dramatically shifted, moving from 'bearish' to 'extremely bullish' (97/100) within a day.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_225310_41cad3a0dc.png" alt="Screenshot 2024-10-16 225310.png">Korro Bio (KRRO)Korro Bio's shares skyrocketed 111% on Wednesday following Wave Life Sciences’ <a href="https://stocktwits.com/news-articles/markets/equity/wave-life-sciences-stock-surges-on-rna-editing-breakthrough/cJczOOPRI5">announcement</a> of early validation for its latest RNA editing technology, a promising breakthrough in the field of genetic medicine.Korro Bio is heavily investing in RNA editing therapies, specifically targeting Alpha-1 Antitrypsin Deficiency (AATD). The company plans to seek regulatory approval by the end of the year to begin clinical trials for its RNA editing treatments.Retail sentiment around the company on Stocktwits has been initiated at ‘extremely bullish’ (97/100).<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_231152_5247ea7ca2.png" alt="Screenshot 2024-10-16 231152.png">For updates and corrections email newsroom@stocktwits.com.Read more:<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-falls-after-robotaxi-event-underwhelms/cJcVcLcR4T">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/abbott-labs-stock-dips-pre-market-on-narrowed-profit-outlook-retail-turns-bearish/cJcz2u7R4D">Abbott Labs Stock Dips Pre-Market On Narrowed Profit Outlook: Retail Turns Bearish</a>

Rising stock prices of 180 Life Sciences, Korro Bio, and NuScale Power fuel bullish retail sentiment on Stocktwits

180 Life Sciences, Korro Bio, NuScale Power: Retail Investors Turn Most Bullish On These Stocks

Small-cap stocks like Korro Bio and NuScale Power are benefiting from the momentum generated by larger stocks.

Korro Bio Board Changes and Strategic Advisor Agreement

An announcement from Korro Bio (KRRO) is now available. David L. Lucchino resigned from our Board of Directors on August 26, 2024, but will stay co...

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer...

Piper Sandler Reiterates Overweight Rating for Korro Bio (NASDAQ:KRRO)

Piper Sandler restated their overweight rating on shares of Korro Bio (NASDAQ:KRRO - Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Piper Sandler currently has a...

We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Korro Bio (NASDAQ:KRRO) Price Target Increased to $115.00 by Analysts at HC Wainwright

Korro Bio (NASDAQ:KRRO  Free Report) had its price target lifted by HC Wainwright from $100.00 to $115.00 in a research note published on Thursday, Marketbeat Ratings reports. The firm...

Korro Bio (NASDAQ:KRRO) Rating Reiterated by Piper Sandler

Korro Bio (NASDAQ:KRRO  Get Free Report)s stock had its overweight rating restated by equities research analysts at Piper Sandler in a report issued on Wednesday, Benzinga...

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$7.57
Prev Close	$32.80
Open	$33.09
Dividend Yield	0.00%
50-Day Moving Average	$38.69
Beta	0.75
Avg. Volume	240,989.39
PE Ratio	-3.22

52-Week High	$57.94
52-Week Low	$10.29
Market Capitalization	$308.02M
EPS (Annual)	-$9.37
Price to Book	2.56
Revenue Per Employee	$21,836.54
Enterprise Value/EBITDA	N/A

KRRO
Korro Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KRRO News

KRROKorro Bio Inc.